Patients were observed off treatment for the occurrence of rebound (PASI  150% of baseline) and for the time to relapse (defined as a loss of at least half of the improvement achieved between baseline and week 24).
Patsiente jälgiti peale ravi lõpetamist ägenemise suhtes (PASI ≥ 150 võrreldes ravi algusega) ja haiguse taastekke (defineeritud kui vähemalt pooles ulatuses paranemisnähtude kadumine) aja suhtes.